Citalopram induced torsade de pointes, a rare life threatening side effect
- PMID: 17919753
- DOI: 10.1016/j.ijcard.2007.08.006
Citalopram induced torsade de pointes, a rare life threatening side effect
Abstract
Acquired Long QT syndrome is a disorder caused by medications, electrolyte imbalances, and drug interactions. This syndrome is associated with an increased risk of a characteristic life-threatening cardiac arrhythmia, known as torsade de pointes (TdP). In the setting of Long QT syndrome (LQTS), selective serotonin reuptake inhibitors (SSRIs) can precipitate TdP. We report the first case of LQTS and TdP induced by citalopram in the United States. After discontinuation of citalopram, the QT/QTc interval normalized after 3 days and resolved further episodes of TdP. Patients on citalopram should be monitored closely for QT/QTc interval to prevent torsade de pointes.
Comment in
-
Citalopram-induced long QT syndrome and torsade de pointes: role for concomitant therapy and disease.Int J Cardiol. 2011 Apr 14;148(2):226-8. doi: 10.1016/j.ijcard.2009.05.060. Epub 2009 Jun 21. Int J Cardiol. 2011. PMID: 19540606 No abstract available.
Similar articles
-
Citalopram-induced long QT syndrome and torsade de pointes: role for concomitant therapy and disease.Int J Cardiol. 2011 Apr 14;148(2):226-8. doi: 10.1016/j.ijcard.2009.05.060. Epub 2009 Jun 21. Int J Cardiol. 2011. PMID: 19540606 No abstract available.
-
A case series of drug-induced long QT syndrome and Torsade de Pointes.Singapore Med J. 2001 Dec;42(12):566-70. Singapore Med J. 2001. PMID: 11989578
-
The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias.J Am Coll Cardiol. 2007 Jan 23;49(3):320-8. doi: 10.1016/j.jacc.2006.08.058. Epub 2007 Jan 4. J Am Coll Cardiol. 2007. PMID: 17239713
-
Drug-induced long QT syndrome and torsade de pointes.Can J Cardiol. 2005 Aug;21(10):857-64. Can J Cardiol. 2005. PMID: 16107909 Review.
-
[Torsade de pointes].Z Kardiol. 1993 Dec;82(12):763-74. Z Kardiol. 1993. PMID: 8147050 Review. German.
Cited by
-
Evaluation of QTc prolongation and dosage effect with citalopram.Ment Health Clin. 2016 Jun 29;6(4):165-170. doi: 10.9740/mhc.2016.07.165. eCollection 2016 Jul. Ment Health Clin. 2016. PMID: 29955465 Free PMC article.
-
Citalopram and cardiac toxicity.Eur J Clin Pharmacol. 2013 Apr;69(4):755-60. doi: 10.1007/s00228-012-1408-1. Epub 2012 Sep 21. Eur J Clin Pharmacol. 2013. PMID: 22996077 Review.
-
Clinical use of antidepressant therapy and associated cardiovascular risk.Drug Healthc Patient Saf. 2012;4:93-101. doi: 10.2147/DHPS.S28804. Epub 2012 Aug 17. Drug Healthc Patient Saf. 2012. PMID: 22936860 Free PMC article.
-
Comparative Cardiac Safety of Selective Serotonin Reuptake Inhibitors among Individuals Receiving Maintenance Hemodialysis.J Am Soc Nephrol. 2019 Apr;30(4):611-623. doi: 10.1681/ASN.2018101032. Epub 2019 Mar 18. J Am Soc Nephrol. 2019. PMID: 30885935 Free PMC article.
-
Evaluating the risk of QTc prolongation associated with antidepressant use in older adults: a review of the evidence.Ther Adv Drug Saf. 2018 Jun;9(6):297-308. doi: 10.1177/2042098618772979. Epub 2018 May 4. Ther Adv Drug Saf. 2018. PMID: 29854391 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources